Article Text

Download PDFPDF

Study and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients
  1. Cyrille Cohen1,
  2. Jared J Gartner2,
  3. Miryam Horovitz-Fried1,
  4. Katerina Shamalov1,
  5. Kasia Trebska-Mcgowan3,
  6. Valery Bliskovsky4,
  7. Maria R Parkhurst3,
  8. Chen Ankri1,
  9. Todd D Prickett5,
  10. Jessica Crystal4,
  11. Yong Li4,
  12. Mona El-Gamil3,
  13. Steven A Rosenberg6 and
  14. Paul F Robbins2
  1. Aff1 grid.22098.310000000419370503Bar-Ilan University Ramat Gan Israel
  2. Aff2 grid.48336.3a0000000419368075Surgery Branch/National Cancer Institute / National Institutes of Health Bethesda MD USA
  3. Aff3 grid.94365.3d0000000122975165NIH/National Cancer Institute Bethesda MD USA
  4. Aff4 grid.94365.3d0000000122975165NIH Bethesda MD USA
  5. Aff5 grid.48336.3a0000000419368075NCI/NIH Bethesda MD USA
  6. Aff6 grid.48336.3a0000000419368075NIH/NCI Bethesda MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


T cell-based immunotherapy shows promise for the successful treatment of advanced cancer. Indeed, adoptively transferred tumor infiltrating T lymphocytes (TIL) that mediated complete regression of metastatic melanoma have been shown to recognize neoantigens/mutated epitopes expressed by autologous tumors.


In the present study, we sought to develop a strategy for facilitating the isolation, expansion and study of T cells specific for neoantigens. We performed whole exome sequencing on matched tumor and normal DNA from eight metastatic melanoma patients. Candidate neo-epitopes, identified using a peptide/MHC binding algorithm, were synthesized and we used those to produce panels of MHC/tetramers that were evaluated for binding to tumor digests and cultured TIL used for patient treatment.


This resulted in the characterization of nine mutated epitopes from five of eight patients tested. Cells reactive with eight of the nine epitopes could be isolated from autologous peripheral blood where they were detected at frequencies that were estimated to range between 0.4% and 0.002%.


To the best of our knowledge, this represents the first demonstration of the successful isolation of mutation reactive T cells from patient peripheral blood prior to immune therapy. Moreover, we were able to rapidly isolate and clone from these cells TCRs specific for neoantigens that could be used to endow T cells with mutated antigens specificity. In addition, neo-antigens reactive T cells were detected in the patient peripheral blood for up to one year after treatment. We believe this potentially provides the basis for designing novel personalized immunotherapies for treating patients with advanced cancer.